UniSC Clinical Trials has begun investigating a potential world-first human chlamydia vaccine to protect against infection and reinfection.

Overall, 1,500 young Australian adults who are sexually active will be recruited to join the study, with the vaccine to be administered at trial sites nationwide.

The first 120 participants will begin receiving the investigational vaccine at UniSC Clinical Trial centres at Southbank, Morayfield and the Sunshine Coast.

Chlamydia infection can affect the reproductive organs of both males and females. Left untreated, it can cause serious complications such as pelvic inflammatory disease and infertility. It is also associated with a higher risk of contracting other sexually transmitted infections.

Current treatment is limited to antibiotics, however there are concerns around the increasing rates of antibiotic resistance with the need to treat recurrent infections.

Often referred to as a "silent" sexually transmitted infection, chlamydia presents with no symptoms in more than 80 percent of cases.

“It is hoped this potential new mRNA vaccine will help prevent health complications from undiagnosed and untreated chlamydia infection,” Dr Evangelista said. 

In Australia, most chlamydia infections occur in people under the age of 30.  

“We are inviting people aged 18 to 29 years, who are in good general health and do not currently have chlamydia to join this trial. Others who have been previously treated for chlamydia are also welcome to apply.”  

Young people interested in taking part will receive free testing for chlamydia and other STIs. Those who are eligible for the clinical trial will be asked to attend 10-13 visits over 18 months.  

For more information or to register, visit UniSC Clinical Trials or call (07) 5409 8640.